Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells

FEBS Open Bio. 2020 Nov;10(11):2375-2387. doi: 10.1002/2211-5463.12985. Epub 2020 Oct 5.

Abstract

Malignant mesothelioma (MM) is an aggressive malignant neoplasm which rapidly invades pleural tissues and has a poor prognosis. Here, we explore enhancement of the effect of irinotecan [camptothecin-11 (CPT-11)] by the p53-dependent induction of carboxylesterase 2 (CES2), a CPT-11-activating enzyme, in MM. The level of CES2 mRNA was greatly increased on treatment with nutlin-3a. A combination of CPT-11 and nutlin-3a inhibited the growth of MM cells more effectively than either drug alone. Knocking down CES2 in MM cells reduced the effect of the drug combination, and its forced expression in MESO4 cells enhanced the growth inhibitory activity of CPT-11 in the absence of nutlin-3a. Enhancement of the growth inhibitory activity of CPT-11 by nutlin-3a suggests a possible new combinatorial MM chemotherapy regimen.

Keywords: carboxylesterase 2; irinotecan; mesothelioma; p53.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboxylesterase / metabolism
  • Cell Death / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Imidazoles / pharmacology
  • Imidazoles / therapeutic use
  • Irinotecan / pharmacology
  • Irinotecan / therapeutic use*
  • Mesothelioma / drug therapy*
  • Mesothelioma / genetics
  • Mesothelioma / pathology*
  • Mutagens / toxicity
  • Piperazines / pharmacology
  • Piperazines / therapeutic use
  • Tumor Suppressor Protein p53 / metabolism*

Substances

  • Imidazoles
  • Mutagens
  • Piperazines
  • Tumor Suppressor Protein p53
  • nutlin 3
  • Irinotecan
  • CES2 protein, human
  • Carboxylesterase